Xilio Therapeutics (XLO) Stock Price, News & Analysis

Company Overview

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for the treatment of cancer. The company’s approach is designed to activate therapeutic agents selectively within the tumor microenvironment, with the goal of stimulating an immune response against cancer while reducing exposure to healthy tissues and the systemic side effects associated with conventional immunotherapies.

Xilio’s product candidates are based on its proprietary tumor-activation technology and include engineered cytokines and immune-oncology antibodies. Its development programs have included tumor-activated versions of interleukin-2, interleukin-12 and anti-CTLA-4 therapies. These candidates are being investigated for potential use in solid tumors, both as standalone treatments and in combination with other cancer therapies.

Headquartered in Waltham, Massachusetts, Xilio Therapeutics was founded in 2015 and became a publicly traded company on the Nasdaq under the symbol XLO in 2021. The company’s activities are primarily focused on research, clinical development and advancing its pipeline of oncology medicines through clinical testing and potential strategic partnerships.

Key Stats

• Today's Range: $8.96 to $9.22
• 50-Day Range: $8.31 to $9.50
• 52-Week Range: $6.47 to $12.74
• Volume: 11,128 shs
• Average Volume: 35,569 shs
• Market Capitalization: $59.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Xilio Therapeutics Stock Analysis - MarketRank™

Xilio Therapeutics scored higher than 6% of companies evaluated by MarketBeat, and ranked 886th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Xilio Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Xilio Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Xilio Therapeutics is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xilio Therapeutics is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xilio Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.78% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 37.36, which indicates bearish sentiment.

Change versus previous month

Short interest in Xilio Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xilio Therapeutics does not currently pay a dividend.

Dividend Growth

Xilio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.79

News Sentiment

Xilio Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.45% of the stock of Xilio Therapeutics is held by insiders.

Percentage Held by Institutions

54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XLO
• CIK: 1840233
• Web: www.xiliotx.com
• Phone: (617) 833-1027
• Fax: N/A
• Employees: 76
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.04 million
• Net Margins: -34.06%
• Pretax Margin: -34.06%
• Return on Equity: -71.99%
• Return on Assets: -20.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.25
• Quick Ratio: 4.25

Sales & Book Value

• Annual Sales: $43.77 million
• Price / Sales: 1.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.31 per share
• Price / Book: 1.24

Miscellaneous

• Outstanding Shares: 6,580,000
• Free Float: 6,090,000
• Market Cap: $59.55 million
• Optionable: Not Optionable
• Beta: -0.14